Literature DB >> 2049732

Clinicopathologic study of large cell anaplastic lymphoma (Ki-1-positive large cell lymphoma) among the Japanese.

S Nakamura1, N Takagi, M Kojima, T Motoori, K Kitoh, H Osada, H Suzuki, M Ogura, S Kurita, A Oyama.   

Abstract

The clinical, prognostic, phenotypic, and genotypic findings of 30 patients with large cell anaplastic lymphoma (Ki-1-positive large cell lymphoma) were analyzed. There were 13 male and 17 female patients (male-female ratio, 0.8) whose ages ranged from 3 to 81 years of age (mean, 28 years of age; 67% of the patients younger than 30 years of age). The 5-year survival rate was 52%; this was better than that of other types of high-grade peripheral T-cell lymphoma. Histologic examination showed distinctive morphologic features such as tumor cell pleomorphism, sinus infiltration, fibrosis, partial lymph node involvement, sparing of B-cell regions, and occasional plasma cell infiltrates. Eighty percent of the cases were of T-cell phenotype, and others expressed neither B-cell nor T-cell markers. The tumors were frequently positive for a histocompatibility antigen (HLA-DR), CD25 (the interleukin-2 receptor), and epithelial membrane antigen. Rearrangements of the T-cell receptor beta gene were observed in nine of 13 cases (69%). These findings indicated that many of the tumors had the phenotype and genotype of activated T-cells. This study also showed that large cell anaplastic lymphoma has a survival figure intermediate between Hodgkin's disease and low-grade peripheral T-cell lymphoma.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2049732     DOI: 10.1002/1097-0142(19910701)68:1<118::aid-cncr2820680123>3.0.co;2-r

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  9 in total

1.  Ki-1 lymphoma with nodular involvement in liver and spleen: possible role of cytokines in systemic manifestation of fever and leukocytosis.

Authors:  Y Harada; S Yamada; S Murakami; S Mine; Y Momosaka; J Tsukada; I Morimoto; S Eto
Journal:  Dig Dis Sci       Date:  2000-11       Impact factor: 3.199

2.  Pericardial involvement as an initial presentation of anaplastic large cell lymphoma.

Authors:  Purushothaman Muthusamy; Stephen Ebrom; Stephen D Cohle; Nasir Khan
Journal:  Can Fam Physician       Date:  2014-07       Impact factor: 3.275

3.  Rapidly growing primary gastric CD30 (Ki-1)-positive anaplastic large cell lymphoma.

Authors:  S Nakamura; K Aoyagi; A Ohkuni; Y Kimura; M Tsuneyoshi; M Fujishima
Journal:  Dig Dis Sci       Date:  1998-02       Impact factor: 3.199

4.  Detection of t(2;5)(p23;q35) translocation by reverse transcriptase polymerase chain reaction and in situ hybridization in CD30-positive primary cutaneous lymphoma and lymphomatoid papulosis.

Authors:  M Beylot-Barry; L Lamant; B Vergier; A de Muret; S Fraitag; B Delord; P Dubus; L Vaillant; M Delaunay; G MacGrogan; C Beylot; A de Mascarel; G Delsol; J P Merlio
Journal:  Am J Pathol       Date:  1996-08       Impact factor: 4.307

Review 5.  Hodgkin Lymphoma: Biology and Differential Diagnostic Problem.

Authors:  Taishi Takahara; Akira Satou; Toyonori Tsuzuki; Shigeo Nakamura
Journal:  Diagnostics (Basel)       Date:  2022-06-20

6.  MACOP-B treatment in patients with Ki-1-positive large-cell anaplastic lymphoma.

Authors:  C Marosi; R Heinz; G Steger; A Fortelny; A Chott; H Hanak; T Radaszkiewicz; M Baur; G Kreiner; I Schwarzinger
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

7.  Relation of CD30 expression to survival and morphology in large cell B cell lymphomas.

Authors:  L A Noorduyn; P C de Bruin; P van Heerde; M M van de Sandt; G J Ossenkoppele; C J Meijer
Journal:  J Clin Pathol       Date:  1994-01       Impact factor: 3.411

Review 8.  Second malignancies in Hodgkin's disease: A review of the literature and report of a case with a secondary Lennert's lymphoma.

Authors:  Ernst Jg Norval; Erich J Raubenheimer
Journal:  J Oral Maxillofac Pathol       Date:  2014-09

Review 9.  T-cell lymphomas, a challenging disease: types, treatments, and future.

Authors:  Helen Ma; Maher Abdul-Hay
Journal:  Int J Clin Oncol       Date:  2016-10-14       Impact factor: 3.402

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.